Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
WNEM Saginaw on MSN
4h
The truth about RSV
It often mimics the common cold, but RSV can quickly turn into bronchiolitis and pneumonia. “The older you get, the milder ...
2d
RSV Can Be a Killer. New Tools Are Identifying the Most At-Risk Kids
RSV infects almost every child before they turn 2, and kills more than 100,000 infants worldwide each year. Machine learning ...
The American Journal of Managed Care
2d
New RSV Vaccine Is Likely Cost-Effective for Older Adults, Study Finds
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
21h
Health Beat: The truth About RSV
Often dismissed as just another common cold, RSV can be deadly, especially for infants and older people. Hannah and her twin ...
4d
Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
5h
After years of advocacy by a pediatrician, all Nunavut babies to get RSV immunization
The Nunavut government says it will provide immunization against respiratory syncytial virus to all infants in the territory ...
Jefferson Public Radio
4h
COVID-19, RSV, flu: Updated shots are available now in Oregon
October: time for muddy soccer practices, cider pressing and Halloweentown ... And time to roll up your sleeves.
Medscape
7d
For Which Adults Are RSV Vaccination Programs Cost-Effective?
Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said.
4d
on MSN
Manitoba not covering RSV treatments for newborns, pregnant people now recommended by federal agency
Manitoba is falling behind on recommendations from a federal public health body to extend an RSV immunization program to help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
GSK
COVID
vaccine
BEYFORTUS
GlaxoSmithKline
Feedback